Daiwa Securities Group Inc. - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 108 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$20.0%2150.0%0.00%
Q2 2023$20.0%2150.0%0.00%
Q1 2023$20.0%2150.0%0.00%
Q4 2022$2
-99.9%
2150.0%0.00%
Q3 2022$2,0000.0%2150.0%0.00%
Q2 2022$2,0000.0%2150.0%0.00%
Q1 2022$2,0000.0%2150.0%0.00%
Q4 2021$2,000
+100.0%
215
+79.2%
0.00%
Q3 2021$1,000
-50.0%
1200.0%0.00%
Q2 2021$2,0000.0%1200.0%0.00%
Q1 2021$2,0000.0%1200.0%0.00%
Q4 2020$2,000
-60.0%
120
-65.5%
0.00%
Q3 2020$5,000
-84.4%
3480.0%0.00%
-100.0%
Q2 2020$32,000
+300.0%
3480.0%0.00%
Q1 2020$8,000
+14.3%
348
+8.8%
0.00%
Q4 2019$7,0000.0%320
-9.3%
0.00%
Q3 2019$7,000
+16.7%
3530.0%0.00%
Q2 2019$6,000
-25.0%
3530.0%0.00%
Q1 2019$8,000
-20.0%
353
+18.1%
0.00%
Q3 2018$10,000
+42.9%
2990.0%0.00%
Q2 2018$7,0000.0%2990.0%0.00%
Q1 2018$7,0002990.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Link Fund Solutions Ltd 5,251,349$135,459,00069.86%
Chescapmanager LLC 949,006$24,570,0003.61%
Baupost Group 9,309,168$241,014,0002.66%
Rock Springs Capital Management LP 655,200$16,963,0000.54%
Rubric Capital Management LP 173,400$4,489,0000.51%
Newtyn Management, LLC 173,300$4,487,0000.41%
NJ State Employees Deferred Compensation Plan 38,142$988,0000.17%
King Wealth Management Group 22,500$583,0000.15%
Virtus ETF Advisers LLC 29,216$756,0000.12%
JACOBS LEVY EQUITY MANAGEMENT, INC 452,615$11,718,0000.12%
View complete list of THERAVANCE BIOPHARMA INC shareholders